Adlerklit9909
The development of a combined immunoassay method, based on a stable isotope tagging strategy and inductively coupled plasma mass spectrometry (ICP-MS), has created options for quantitative bioanalysis. The aim of the study was to develop a combined immunoassay, featuring ICP-MS and a stable element labeling strategy, for the detection of human chorionic gonadotropin (HCG), and developed methodology applicable for clinical practice.
In accordance with guidelines published by the Clinical and Laboratory Standards Institute (CLSI), we developed our assay and then evaluated its analytical performance, including the limit of detection (LOD), the upper limit of quantification (ULoQ), linearity, precision, recovery, cross reactivity, and interference. Next, we collected 130 clinical samples for analysis with the new assay. The data derived from our assay were then compared with those derived by an existing electrochemiluminescence immunoassay (ECLIA).
The LOD of the assay was 0.33 mIU/mL and the ULoQ was 11,30abeling based immunoassay for HCG detection was established successfully and the general performance of this system was acceptable, thus indicating that the assay has potential for the clinical application.
A number of pharmaceutical agents have limited water solubility and are therefore often prepared in a lipid emulsion. Emulsion renders plasma opaque and this could interfere with the accuracy of some standardized laboratory measurements, especially for optical or mechanical based assays. We determined the interference on some laboratory diagnostic values of blood specimens after propofol addition in vitro as well as in vivo when infused into swine.
In vitro, laboratory parameters were measured immediately after mixing swine blood diluted with increasing amounts of propofol emulsion in the range of 3 to 23%, v/v. The contact time of a 9% v/v mixture of blood and propofol was also examined over a 3-hours period. Saline-diluted samples served as controls. Cellular volume, hematocrit, hemoglobin, potassium, and coagulation were measured with various instruments. In addition, similar parameters were analyzed from swine blood following a 9 - 10 hours infusion with propofol/fentanyl compared to infusion with ketwith optical, mechanical or ion selective electrode methodology. Although in vivo samples may be less impacted, there is still a risk of deviation from accuracy.
For Coronavirus Disease 2019 (Covid-19) infection, clinical laboratories provide essential contributions in the diagnosis of infection, stage prognostication, and evaluation of disease severity. We aimed to show laboratory problems including changes of test numbers, changes of test panels, and differences of preanalytical errors during Covid-19 pandemic and, in the current study, we also intended to give solutions for the obstacles to guide other possible pandemics.
Our study was based on data between January 10, 2020, and May 10, 2020. The first Covid-19 case of the Republic of Turkey was seen March 10, 2020, which was determined as the threshold date for comparisons. This was a single center, data mining, retrospective study.
The number of patients admitted to hospital were 34,260 and 15,573, the number of total tests were 66,263 and 42,066 before and after pandemic, respectively, for the two-month interval. Test percentage changes were increased for D-dimer 136%, fibrinogen 3,113%, troponin 6%, and LDH 17%. NSC 27223 chemical structure Test percentage changes were decreased for CBC 37%, sedimentation 45%, aPTT 30%, PT 37%, CRP 28%, ProCT 10%, ferritin 29%, CK-MB 27%, blood gases 47%, ALT 43%, AST 42%, urea 42%, creatinine 42%, triglycerides 45%, sodium 42%, potassium 41%, chloride 21%, urine culture 58%, and blood culture 44%. When preanalytical sources of errors were investigated no differences were found.
Laboratories must take quick action and be prepared for changes in patient services during pandemics. The most reliable ways for this are past experiences, statistical analysis, co-operation with administrations, high quality communication skills, and a risk-based management system.
Laboratories must take quick action and be prepared for changes in patient services during pandemics. The most reliable ways for this are past experiences, statistical analysis, co-operation with administrations, high quality communication skills, and a risk-based management system.
Tuberculosis is one of the main infectious diseases threatening human health, especially in HIV co-infected patients. Xpert® MTB/RIF assay amplifies the rpoB gene of MTB was recommended by the World Health Organization as the initial diagnostic test in cases of suspected infections with Mycobacterium tuberculosis (MTB) or HIV-coinfected TB.
A 44-year-old male HIV-positive patient co-infected with MTB presented with low-grade fever for 3 months. Rifampicin (RIF) resistance was detected in the celiac pus but not in the pleural effusion using Xpert® MTB/RIF assay. The same samples were then sequenced by next-generation sequencing (NGS) and in-house PCR for rpoB gene.
The results of NGS and in-house PCR, however, were paradoxical in the same samples with low or no mutation sequences of RIF resistance. The patient's tuberculosis (TB) therapy was optimized based on first-line anti-TB drugs and antiretroviral treatment. The patient improved with this therapy.
Even with high specificity, false positive results remain possible and RIF resistance detection by Xpert must be considered for clinical interpretation.
Even with high specificity, false positive results remain possible and RIF resistance detection by Xpert must be considered for clinical interpretation.
Neurofibromatosis (NF) is a genetic disorder, and neurofibromatosis types 1 and 2 have different genetic and clinical features. Herein, we present the clinical and genetic aspects of a patient carrying a constitutional NF1 gene mutation and whose neurocutaneous manifestations suggested a NF type 2 (NF2).
A 55-year-old woman presented with headache and deterioration of vision. Physical examination and radiologic findings revealed multiple subcutaneous nodules and multiple intracranial and spinal masses which were suspected to be NF2.
Genomic DNA sequencing using a peripheral blood sample revealed a splicing mutation in the NF1 gene. Tumor resection and biopsy revealed intracranial meningiomas and paraspinal Schwannoma compatible with NF2. PCR-direct sequencing using tumor tissue samples showed pathogenic somatic mutation of the NF2 gene.
We report a case of NF2 presenting with a pathogenic somatic mutation in the NF2 gene in a woman harboring a germline splicing mutation in the NF1 gene. This case emphasizes the importance of sequence analy¬sis by using tumor tissues and the need to elucidate the role of a NF1 splicing mutation.
